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ABSTRACT
Introduction: Among the most ordinary clinical manifestations of Multiple Sclerosis 
(MS) are depression and the presence of Lower Urinary Tract Symptoms (LUTS). 
Both can compromise a person’s quality of life. The objective of this research was to 
identify the major urinary symptoms and correlate them with quality of life and with 
depressive symptoms in women with MS. 
Methods: This was an observatory, descriptive and correlational study, with non-
probabilistic sampling by convenience. This research included women over 18 years old 
who displayed LUT symptoms and who had been diagnosed with Relapsing-Remitting 
MS. Assessment consisted of an anamnesis card, the Kurtzke Expanded Disability Status 
Scale (EDSS), the Incontinence Impact Questionnaire-7 (IIQ-7-BR), the Urogenital 
Distress Inventory-6 (UDI-6-BR), the Beck Depression Inventory-2 (BDI-II) and the 
Multiple Sclerosis Quality of Life Questionnaire - Portuguese version (MSQOL-54). 
Results: 41 women participated in the study, with average age of 50.1 (± 9.45) and 
average of 4.11 in the EDSS. The most common urinary symptom was urinary urgency 
(78%). There was no correlation between the severity of the urinary symptom and 
quality of life. Moderate and significant negative correlation (r = -0.561 p < 0.001) was 
found between depression and the physical component of quality of life and strong 
negative correlation (r = -0.729 p < 0.001) was found between depression and the 
mental component. 
Conclusions: The most prevalent urinary symptom was urinary urgency. A strong 
correlation was found between symptoms of depression and quality of life and there 
was no correlation between urinary symptoms and quality of life. 
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Multiple Sclerosis (MS) is a chronic, progressive, autoimmune, highly 
disabling disease1. It causes central nervous system (CNS) demyelination, 
in which the oligodendrocytes and myelin sheath are the main targets of 
inflammatory processes, causing motor, cognitive, sensory, and urogenital 
damage, interfering with the autonomy and functioning of patients1.
MS affects individuals between the ages of 20 and 40 and is more common 
in women, at a 2-by-1 ratio, which tends to increase and reach 3-by-12. In Brazil, 
the prevalence of MS varies greatly according to geographical distribution. 
The city with the highest prevalence rate is Santa Maria, state of Rio Grande 
do Sul, with 27.2 cases per 100,000 inhabitants3. MS can be classified into four 
subtypes, depending on the clinical course of the disease2. The most frequent 
is Relapsing-Remitting MS (or remission), in which episodes of exacerbation 
of symptoms are interspersed with intervals or remissions, presenting a slow 
progression. The most common clinical manifestations are: fatigue, loss of 
strength, diplopia, sensitivity and coordination alterations, emotional changes 
and urogenital dysfunctions2.
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Depression affects up to 50% of people with MS 
and is regarded as a common alteration related to 
vegetative changes and functional disability4. Lower 
Urinary Tract Symptoms (LUTS) are also highly incident 
in this public; they affect most patients who have had MS 
for longer periods5 and may manifest in several ways: 
detrusor overactivity (drowsiness, increased voiding 
frequency and urge incontinence), bladder sphincter 
dyssynergia, and detrusor insufficiency (associated 
with residual urine, incomplete emptying, hesitation, 
and interrupted flow).
Although these disorders are highly prevalent and 
seem to significantly affect the lives of people with 
MS, they are often underdiagnosed as suggested 
by Akkoç et al.6, making it difficult to understand 
the connection between these symptoms and their 
associated factors. 
OBJECTIVE
The objective of this study was to identify the 
main urinary symptoms and to correlate them with 
Quality of Life and with depressive symptoms in 
women with MS treated at the Hospital de Clínicas 
of Porto Alegre (HCPA), Brazil. 
METHODS
This is an observational study with a descriptive 
and correlational design. This study was 
approved by the Research Ethics Committee 
of the Hospital de Clínicas of Porto Alegre 
(CAAE number: 52443615300005327). The fieldwork 
was carried out from March to September 2016.
Population and sample
Patients undergoing follow-up treatment at the 
Multiple Sclerosis outpatient clinic of the Hospital 
de Clínicas of Porto Alegre participated in the study. 
Participants were invited while they were in the 
waiting room for a previously scheduled medical 
appointment. Thus, the study sample was non-
probabilistic by convenience. The inclusion criteria 
were: women aged 18 years and over, diagnosed 
with Relapsing-Remitting MS, and with LUTS (such 
as frequent urination, nocturia, urinary urgency 
and/or urinary incontinence). Exclusion criteria 
were: clinical diagnosis of urinary tract infection, 
pregnancy or puerperal state, comprising a period 
of up to 6 months. 
Procedures for collection and analysis
All patients were previously informed about 
the collection procedures and the purposes of the 
investigation. When they agreed to participate in 
the research, they signed an Informed Consent Form.
Collection procedures occurred on the same day. 
They were performed by the same assessor and 
occurred in 4 stages:
1) Anamnesis file with information on urinary 
symptoms (nocturia, urgency, voiding frequency and 
urinary retention), obstetric history, classification on 
the Kurtzke Expanded Disability Status Scale (EDSS)7 
to assess MS, and records of the medications used; 
2) Beck Depression Inventory-2 (BDI-II), a self-rated 
scale containing 21 items, which assesses depression 
signs and symptoms. The total score ranges from 0 
to 63 points; from 0 to 13 points, minimal depression/
no depression; 14 to 19 points, mild depression; 20 
to 28 points, moderate depression; and 29 to 63 
points, severe depression8. 
3) Incontinence Impact Questionnaire-7 (IIQ-7-BR), 
the Urogenital Distress Inventory-6 (UDI-6-BR). Both 
questionnaires are self-administered instruments, 
composed of 7 and 6 questions, respectively, with the 
purpose of measuring the impact of UI on the quality of 
life of people with MS. IIQ-7-BR has a maximum score 
of 21 points; the closer to 21, the greater the impact 
of UI on daily living activities and physical activities. 
UDI-6-BR is composed of three subscales: the first 
assessed symptoms of urinary stress (urgency, frequency 
and pain) (questions 1 and 2); the second assesses stress 
symptoms (questions 3 and 4); and the third, obstruction/
residue or discomfort in the region (questions 5 and 6). 
It has a maximum score of 18 points; the closer the 
score is to 18, the more severe the symptoms9. Neither 
the IIQ-7-BR questionnaire nor the UDI-6-BR has a 
previously established cut-off point. 
4) Multiple Sclerosis Quality of Life Questionnaire 
(MSQOL-54). It has recently been translated into 
Portuguese and validated. It is a self-administered 
instrument with 35 generic questions, 17 specific 
ones, and 2 separate questions: one about change in 
health status and the other about sexual satisfaction. 
The scale items are grouped into 12 subscales that 
result in two major components: physical and mental 
health. The scores of the subscales vary from 0 to 
100, and higher values indicate a better quality of life10.
The anamnesis form was applied by a professional 
and the questionnaires were self-administered. 
Statistical Analysis
The sample size was calculated by the Statistical 
Analysis System (SAS) software, version 9.4, aiming 
to estimate and test a linear association between the 
quantitative variables of the Quality of Life Score 
(MSQOL-54), depressive symptoms (BDI-II) and 
urinary symptoms (IIQ-7-BR and UDI-6-BR). With 
a “p” value of ≤ 0.05, power of 90% and minimum 
correlation of 0.6, a minimum sample size of 39 
participants was defined.
The Shapiro-Wilk test was performed to verify the 
normality of the data. The variables were described 
by average and standard deviation for continuous 
quantitative variables with symmetric distribution, 
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and median and interquartile range for continuous 
variables, with asymmetric distribution. Categorical 
variables were described by absolute frequency and 
relative frequency. In the inferential analysis, the 
correlation of the variables was carried out through 
the Spearman’s rank correlation test. All analyses 
considered a significance level of 5% (p = ≤ 0.05) and 
were performed by the Statistical Package for Social 
Sciences (SPSS), version 21.0.
RESULTS
On average 200 patients were being treated at 
the outpatient clinic and according to the consultation 
schedule, the patients that fit the selection criteria 
were invited until the sample size was reached. 
A total of 41 women participated in the study, the 
majority overweight according to the World Health 
Organization. The average EDSS score was 4.1, 
classifying the patients as having moderate disabilities 
caused by MS, according to the classification used 
by Ferreira et al.11 and most of the sample (58.5%) 
had the disease for 10 years or more (Table 1).
According to the classification of the Beck Depression 
Inventory-2 (BDI - II), 73.2% of the participants presented 
symptoms indicative of depression. Regarding quality 
of life, the median of the physical component was 
apparently lower (md = 45) when compared to the 
mental component (md = 50), indicating that the 
physical aspects – such as independence, autonomy, 
pain, sexual function, energy, fatigue and physical 
limitations – resulted in lower scores, which may refer 
to a worse quality of life regarding this aspect. (Table 1).
The most common urinary symptom was urinary 
urgency, reported by 78% of the sample, followed 
by difficulty in emptying the bladder (70%). Other 
characteristics about urinary symptoms are show 
in Table 2. 
A moderate and significant negative correlation 
(r = -0.561 and p ≤ 0.001) was found between depression 
and the physical component of quality of life, and a 
strong and negative significant correlation (r = -0.729 
and p ≤ 0.001) was found between depression and the 
mental component of quality of life, which demonstrates 
that the more severe the symptoms indicative of 
depression, the worse the quality of life (Figure 1). 
Table 1: Characteristics of the sample.
Variables n = 41
Age (years) – average ± SD 50.1 ± 9.45
BMI – average ± SD 26.93 ± 4.72
Time since diagnosis (months) – md (P25-P75) 132 (51 – 192)
Menopause – n (%) 20 (49.0)
Type of birth – n (%)
Vaginal delivery 38 (57.6)
Cesarean delivery 28 (42.4)
Episiotomy – n (%) 10 (24.3)
Multiparous – n (%) 22 (53.6)
Nulliparous – n (%) 15 (36.5)
Primiparous – n (%) 8 (19.5)
Use of pads – n (%) 22 (53.6)
EDSS classification – n (%)
Mild (0 – 3.5) 17 (41.5)
Moderate (4 – 6.5) 19 (46.3)
Severe (7 +) 5 (12.2)
MSQOL - md (P25- P75)
Physical component 45 (37 – 52)
Mental component 50 (34.5 – 57)
BDI-II– md (P25- P75) 19 (12 – 26)
Classification of depression – n (%)
No depression 11 (26.8)
Mild depression 12 (29.3)
Moderate depression 11 (26.8)
Severe depression 7 (17.1)
SD = Standard Deviation; EDSS = Kurtzke Expanded Disability Status Scale; MS = Multiple Sclerosis; md = median; P25 = Percentile 25; 
P75 = Percentile 75; MSQOL-BR = Multiple Sclerosis Quality of Life Questionnaire – Portuguese; BDI-II = Beck Depression Inventory-2.
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A strong correlation was found between UDI-6-BR 
and IIQ-7-BR (r = 0.719 and p ≤ 0.001), indicating 
that the greater the severity of urinary symptoms, 
the greater their impact. A weak negative correlation 
was found between the severity of MS according to 
EDSS and the urinary symptoms, possibly showing 
that more severe urinary symptoms manifested in 
participants with lower disability. Regarding the impact 
of urinary symptoms, a weak negative correlation was 
found only with the physical component of quality of 
life. There was no significant correlation between the 
other analyzed variables (Table 3). 
Table 2: Characteristics of the lower urinary tract symptoms.
Variables n = 41
Urinary symptoms
Urinary urgency – n (%) 32 (78.0)
Urine retention – n (%) 29 (70.7)
Frequent urination – n (%) 24 (58.5)
Nocturia – n (%) 19 (46.3)
Mixed urinary incontinence – n (%) 15 (36.5)
IIQ-7 – md (P25-P75)  8 (2 – 11)
UDI- 6 – md (P25 – P75) 7 (4-10)
IIQ-7 = Incontinence Impact Questionnaire-7; UDI-6 = Urogenital 
Distress Inventory-6; md = median; P25 = Percentile 25; 
P75 = Percentile 75. 
Table 3: Association between the variables through Spearman’s rank correlation coefficient.
Association Correlation Coefficient p
IIQ7 x UDI6 0.719* <0.001
EDSS x UDI6
IIQ7 x MSQOL – Physical Component
IIQ7 x MSQOL – Mental Component
UDI6 x MSQOL – Physical Component











EDSS x IIQ7 -0.056 0.366
EDSS x BDI II 0.121 0.229
EDSS x MSQOL – Physical Component -0.175 0.140
EDSS x MSQOL – Mental Component 0.136 0.202
Time since diagnosis of MS x UDI6 





IIQ-7 = Incontinence Impact Questionnaire-7; UDI-6 = Urogenital Distress Inventory-6; EDSS = Kurtzke Expanded Disability Status Scale; 
Multiple Sclerosis Quality of Life Questionnaire – Portuguese; BDI-II = Beck Depressionventory-2; MS = Multiple Sclerosis
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Figure 1: Association between the depression score BDI with the physical (A) and mental (B) components of the 
MSQOL score.
Regarding the drugs used to control MS, 48.7% of 
the patients used glatiramer acetate (Copaxone®), 22% 
used Fingolimod (Gilenya®), and 17% used Interferon 
beta-1a (Avonex®). As to other drugs used by the 
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patients, 61% of the sample used antidepressants, 
the most common ones including Amitriptyline 
(22%), Fluoxetine (22%), and Sertraline (9.7%). 
Regarding diuretic medication, 12.1% used 
Hydrochlorothiazide, and, to control urinary symptoms, 
only 9.7% used Oxybutynin.
None of the women assessed received treatment 
for their LUTS previously; after evaluation and 
identification of the symptoms, all patients received 
guidance and treatment referral. 
DISCUSSION
The present study aimed to identify the most 
common urinary symptoms and their impact as 
well as and depressive symptoms on the quality of 
life of women with MS undergoing follow-up care at 
HCPA. The average age of the 41 participants was 
50.1 years; the average time since diagnosis of MS was 
132 months; the most common urinary symptom was 
difficulty in emptying the bladder, and no correlation 
was found between severity and impact of urinary 
symptoms with quality of life. Depression correlated 
with poorer quality of life in both the physical and 
mental components. In the sample studied, vaginal 
deliveries were more prevalent; 48% of the sample 
was postmenopausal, 55% were multiparous and 
of the 21 women who underwent a vaginal delivery, 
71.4% had an episiotomy.
As to the age of the participants, time since 
diagnosis of MS and classification by EDSS, the 
findings of this study relate to the results of another 
study that assessed a greater number of participants12. 
The study by Akkoç et al.6 found that urinary urgency 
was the most prevalent symptom (62%), followed by 
frequent urination (50.4%), Urge Urinary Incontinence 
(UUI) (44.7%), and nocturia (33%). In this study, 
urinary urgency was also the most prevalent symptom 
(78%), but, different from the findings by Akkoç et al.6 
 difficulty in emptying the bladder was the second 
most frequently reported urinary symptom, almost 
as prevalent as urinary urgency (70.7%). 
In this study, Mixed Urinary Incontinence (MUI) was 
slightly more prevalent. This finding corroborates the 
results of previous studies5,13 and may be related to the 
fact that MS patients may present with both detrusor 
muscle abnormality (urgency symptoms and vesical 
hyperactivity) and sphincter disorders (stress-related 
symptoms)12,14. In addition, the studied sample seems 
to be susceptible to risk factors related to MUI, such 
as vaginal delivery, more than one pregnancy, and 
menopause, which may also explain the prevalence 
of MUI in this sample and corroborates findings from 
other studies in which MUI was also more prevalent 
in samples susceptible to these risk factors15.
In this study, it was not possible to establish a 
relevant correlation between the impact (IIQ-7-BR) 
and severity (UDI-6-BR) of urinary symptoms with the 
quality of life of participants. In both questionnaires, 
the medians of the scores were low, demonstrating that 
the urinary symptoms presented were not serious and, 
therefore, did not have a great impact on the quality 
of life, that is, the urinary symptoms presented did not 
cause the participants to stop participating in social 
activities outside of home, meeting with family and 
friends, performing self-care, hygiene and domestic 
life activities, for example. One important factor that 
may be related to the fact that urinary symptoms are 
not severe in the sample studied is that none of the 
assessed women was going through the outbreak of 
MS. It is known that sphincter syndrome symptoms are 
related to the evolutionary symptoms of the disease, 
that is, the outbreaks aggravates, or pre-disposes, the 
appearance of these symptoms16. In addition, 
the urinary symptoms may have been influenced 
by the drugs used in treatment, such as Amitriptyline, 
used by 22% of the sample. This substance has an 
anticholinergic action, decreasing bladder contractility 
and minimizing urinary symptoms17.
Still, one hypothesis regarding the limitations of 
the study is the subjectivity of the evaluation of the 
symptoms through self-administered questionnaires, 
since the patient’s mood and other difficult-to-control 
variables can interfere in the responses and come up 
with data that are not so compatible with the severity 
or reality of the symptoms. 
Previous studies14,5,18 suggest that the longer the 
time since the diagnosis of MS, the greater the 
frequency and severity of urinary symptoms. However, 
this study found that there was no correlation 
between the time since diagnosis of MS, severity 
and the impact of urinary symptoms. In addition, 
there was a weak correlation between EDSS and 
the severity of urinary symptoms, indicating that, 
in this sample, these symptoms did not develop along 
with disease progression, suggesting the importance 
of early follow-up treatment for patients with MS, 
in order to identify these symptoms and prevent them 
from getting worse. Mahajan et al.19 also used the 
UDI-6-BR to assess urinary symptoms, and found 
that 65% of participants had at least one moderate 
to severe symptom. These symptoms were also 
assessed by the Overactive Bladder Questionnaire 
and showed a correlation with longer diagnosis time, 
with greater physical disability, and lower quality of 
life scores, corroborating the idea that more severe 
urinary symptoms have a greater impact on the 
lives of people with MS, which was not observed 
in this study. 
There was also no correlation between the time 
since diagnosis of MS and quality of life, corroborating 
the findings of Albuquerque et al.20, which demonstrated 
that the duration of the disease was not associated 
with quality of life when assessed by the MSQOL-54. 
Catarino et al.
http://seer.ufrgs.br/hcpaClin Biomed Res 2019;39(3)198
This shows the multidimensionality and subjectivity 
involved in the evaluation of quality of life, since it is 
influenced by psychological, social, emotional, and 
family factors, not only by the presence or evolution 
of a disease. 
As to the association between depression and MS, 
Marrie et al.21 demonstrated, in a systematic review, that 
the association between depression and psychiatric 
disorders in people with MS is more common in the 
age group from 45 to 59 years. Depression, along with 
anxiety, are the most common psychiatric disorders 
in MS, and can affect up to 70% and 36% of people, 
respectively. The results found by these authors are in 
line with this study, since 30 patients (73%) presented 
symptoms possibly related to depression, and our 
sample had a mean age of around 50 years old. 
Studies indicate that the development or aggravation 
of depression in people with MS is related to the 
impairment of physical abilities, since this impairment 
causes increased dependence to perform basic 
activities and causes patients to need more support 
from relatives and caregivers, often causing anxiety 
and emotional stress22. In this context, the results of 
this study showed that depression is directly related 
to the impairment of physical capacities and the 
emotional aspect of patients with MS. It can also 
be assumed that depression in people with MS may 
be related to the type of support they receive from 
family, caregivers and health professionals, which is 
an important environmental factor to be considered 
in the assessment of MS patients using the ICF23.
There was no correlation between depression, 
quality of life, and the EDSS score. These results 
may be related to the fact that EDSS is an outpatient 
assessment tool that only takes into account disabled 
bodily functions, not emphasizing issues related with 
activity and participation24 components, which are 
assessed in the quality of life questionnaire used in 
this research.
A possible bias in the study is the fact that the 
sample was not random, but by convenience; 
however, since the aim of the study was to assess only 
patients with urinary disorders, the type of sampling 
did not necessarily interfere with the results. Even 
though the sample size was reached, the sample 
of this study is relatively small, and multicenter 
cohort studies with follow-up are necessary to more 
accurately determine the relationship between the 
studied variables. This study identified that 
the most prevalent urinary symptoms in the studied 
sample were voiding urgency, difficulty in emptying 
the bladder, and MUI, but no correlation was found 
between the severity of these symptoms and the 
quality of life. Regarding the signs and symptoms of 
depression, a strong correlation of these symptoms 
with quality of life was found in both the physical 
and mental aspects. In this sense, the results of this 
study emphasize the importance of an adequate 
and early assessment of these symptoms. However, 
more studies are necessary to better understand 
the relationship and impact of these outcomes in 
the life of patients with MS. 
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